DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Woo Jung | ko |
dc.contributor.author | Noh, Hyun Jong | ko |
dc.contributor.author | Noh, Young-Woock | ko |
dc.contributor.author | Kim, Sohyun | ko |
dc.contributor.author | Um, Soong Ho | ko |
dc.contributor.author | Lim, Yong Taik | ko |
dc.date.accessioned | 2023-03-17T03:00:35Z | - |
dc.date.available | 2023-03-17T03:00:35Z | - |
dc.date.created | 2023-03-17 | - |
dc.date.created | 2023-03-17 | - |
dc.date.created | 2023-03-17 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.citation | CARBOHYDRATE POLYMERS, v.155, pp.1 - 10 | - |
dc.identifier.issn | 0144-8617 | - |
dc.identifier.uri | http://hdl.handle.net/10203/305667 | - |
dc.description.abstract | A novel powder-form combination adjuvant system containing two immunostimulatory compounds was firstly developed and evaluated as a therapeutic intervention for cancer immunotherapy. With the help of hyaluronic acid (HA), water insoluble monophosphoryl lipid A (MPL), QS21 and imiquimod (R837), could be easily dispersed in aqueous solution and lyophilized as powder-form, which have an advantage in room-temperature storage stability compared with those conventional liquid formulation that requires cold storage. Two kinds of HA-based combination vaccine adjuvants (HA/MPL/QS21, HMQ and HA/MPL/R837, HMR) contributed to the increase of both humoral and cellular immunity, which is very important for efficient cancer immunotherapy. Through the challenge experiments in EG7-OVA (mouse lymphoma-expressing OVA) tumor-bearing mice model, we found out that the immunostimulatory effects of HMQ and HMR were successful in the inhibition of tumor proliferation. Taken together, both HA-based powder-form combination adjuvant systems are expected to be used as potent prophylactic and therapeutic cancer vaccine. (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Hyaluronic acid-supported combination of water insoluble immunostimulatory compounds for anti-cancer immunotherapy | - |
dc.type | Article | - |
dc.identifier.wosid | 000386402600001 | - |
dc.identifier.scopusid | 2-s2.0-84983242579 | - |
dc.type.rims | ART | - |
dc.citation.volume | 155 | - |
dc.citation.beginningpage | 1 | - |
dc.citation.endingpage | 10 | - |
dc.citation.publicationname | CARBOHYDRATE POLYMERS | - |
dc.identifier.doi | 10.1016/j.carbpol.2016.08.040 | - |
dc.contributor.localauthor | Shin, Woo Jung | - |
dc.contributor.nonIdAuthor | Noh, Hyun Jong | - |
dc.contributor.nonIdAuthor | Noh, Young-Woock | - |
dc.contributor.nonIdAuthor | Kim, Sohyun | - |
dc.contributor.nonIdAuthor | Um, Soong Ho | - |
dc.contributor.nonIdAuthor | Lim, Yong Taik | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | Powder-form adjuvant | - |
dc.subject.keywordAuthor | Immunostimulation | - |
dc.subject.keywordAuthor | Hyaluronic acid | - |
dc.subject.keywordAuthor | Cellular immunity | - |
dc.subject.keywordPlus | MONOPHOSPHORYL-LIPID-A | - |
dc.subject.keywordPlus | IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | AGONIST IMIQUIMOD | - |
dc.subject.keywordPlus | INFLUENZA VACCINE | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | TLR7 AGONIST | - |
dc.subject.keywordPlus | ADJUVANT | - |
dc.subject.keywordPlus | OLIGONUCLEOTIDES | - |
dc.subject.keywordPlus | ENHANCEMENT | - |
dc.subject.keywordPlus | INFECTION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.